New CEO Linus Bosaeus brings a commercial focus

”We plan to have a fully certified product on the market by 2023, but the method is already being tested in healthcare for use as soon as possible”, says Linus Bosaeus, new CEO of Rarity Bioscience AB in interview on Uppsala University Invest.

Read the full article at
(Article in Swedish)

Share this article

Recommended articles